We’ve covered many different aspects of pharmaceutical innovation, ranging from organizational structure, patents, and incubators, but are there...

Although pharmaceutical companies and contract research organizations operate in the same preclinical drug discovery space, working for the two...

Here at Scientist, for the past few weeks we’ve been running a series of blog posts about stem cells discussing why iPS make an attractive research...

In the field of synthetic chemistry, the “elephant in the room” is that chemists spend most of their time just trying to reproduce published...

In our previous post on stem cells, we discussed how human-derived induced pluripotent stem cells (iPS) are being used to model “disease in a...

Carlsbad, CA is soon to be home to San Diego’s own community laboratory space. Much along the lines of Genspace in NYC and BioCurious in Sunnyvale...

Pharmaceutical innovation doesn’t just happen because a lot of money is thrown at it or the company has been restructured. It requires a setting...

Last week we talked about Stem cell research getting the “green light” and this week we continue with our stem cell blog series. Biology has long...

One welcome result of the pharmaceutical innovation crisis is a shift from blockbuster drugs to rare disease drugs. We are doing our own part to...

One of Scientist’s most popular blog posts of last year was an infographic depicting American attitudes towards stem cell research. Part of that...